Evaluating the utility of digital phenotyping to predict health outcomes in schizophrenia: protocol for the HOPE-S observational study

• Published in: BMJ open Vol. 11; no. 10; p. e046552
• Main Authors: Abdul Rashid, Nur Amirah, Martanto, Wijaya, Yang, Zixu, Wang, Xuancong, Heaukulani, Creighton, Vouk, Nikola, Buddhika, Thisum, Wei, Yuan, Verma, Swapna, Tang, Charmaine, Morris, Robert J T, Lee, Jimmy
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 20.10.2021; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Behavior; Biomarkers; Clinical significance; Cognition & reasoning; Cognitive ability; Humans; Illnesses; Mental Health; Observational studies; Observational Studies as Topic; Outcome Assessment, Health Care; Privacy; psychiatry; Psychosis; Remission (Medicine); Schizophrenia; schizophrenia & psychotic disorders; Sensors; Sleep; Smartphone; Smartphones; Social research; Wearable computers; Wearable Electronic Devices; Singapore; schizophrenia & psychotic disorders; mental health; psychiatry
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2020-046552

IntroductionThe course of schizophrenia illness is characterised by recurrent relapses which are associated with adverse clinical outcomes such as treatment-resistance, functional and cognitive decline. Early identification is essential and relapse prevention remains a primary treatment goal for long-term management of schizophrenia. With the ubiquity of devices such as smartphones, objective digital biomarkers can be harnessed and may offer alternative means for symptom monitoring and relapse prediction. The acceptability of digital sensors (smartphone and wrist-wearable device) and the association between the captured digital data with clinical and health outcomes in individuals with schizophrenia will be examined.Methods and analysisIn this study, we aim to recruit 100 individuals with schizophrenia spectrum disorders who are recently discharged from the Institute of Mental Health (IMH), Singapore. Participants are followed up for 6 months, where digital, clinical, cognitive and functioning data are collected while health utilisation data are obtained at the 6 month and 1 year timepoint from study enrolment. Associations between digital, clinical and health outcomes data will be examined. A data-driven machine learning approach will be used to develop prediction algorithms to detect clinically significant outcomes. Study findings will inform the design, data collection procedures and protocol of future interventional randomised controlled trial, testing the effectiveness of digital phenotyping in clinical management of individuals with schizophrenia spectrum disorders.Ethics and disseminationEthics approval has been granted by the National Healthcare Group (NHG) Domain Specific Review Board (DSRB Reference no.: 2019/00720). The results will be published in peer-reviewed journals and presented at conferences.Trial registration numberNCT04230590.